Medline Inc. is under investigation by Kaplan Fox & Kilsheimer LLP for potential securities violations following an FDA warning about significant manufacturing practice breaches. The FDA highlighted failures in investigating batch discrepancies and microbial contamination, leading to a 7.16% drop in Medline's stock price. This is the second FDA action against Medline in two months, raising concerns about the company's compliance and future regulatory scrutiny. Investors who suffered losses are encouraged to contact the law firm for possible legal action.
Regions Financial Corporation's stock surged to a 52-week high of $32.47 following a Jefferies analyst upgrade raising the price target to $32. The bank reported strong Q2 2026 adjusted earnings of $0.68 per share, beating estimates of $0.64, driven ...
Several key stocks fell significantly due to company-specific issues. Intuitive Surgical's shares dropped 14.15% despite strong earnings because of slower growth in surgical procedures, impacting related leveraged ETFs. REGENXBIO's stock fell 11.7% a...
DBV Technologies has filed a prospectus with the U.S. SEC to renew its At-The-Market (ATM) offering program, allowing it to raise up to $150 million by selling American Depositary Shares (ADSs). The funds will primarily support expanding manufacturin...
Glencore has amended and restated its $5 million convertible loan agreement with Tantalex Lithium Resources Corporation, splitting the loan into three facilities with adjusted terms and interest rates. The amended agreement includes a 1% gross revenu...
A Race Against Blindness, an Arizona nonprofit, has launched its first electric vehicle fundraiser featuring a 2025 Volkswagen ID. Buzz and $20,000 cash as the grand prize. Running from July 13 to 26, the campaign aims to raise funds for clinical tri...
